These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37532180)

  • 1. CD47 and PD-L1 overexpression in proliferating human hepatocytes attenuated immune responses and ameliorated acute liver injury in mice.
    Ma C; Cao H; Sun Z; Deng Q; Liu W; Xin Y; Qiao S; Cen J; Shu Y; Qi K; Han L; Zhang L; Pan G
    Am J Transplant; 2023 Dec; 23(12):1832-1844. PubMed ID: 37532180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.
    Lian S; Xie R; Ye Y; Xie X; Li S; Lu Y; Li B; Cheng Y; Katanaev VL; Jia L
    EBioMedicine; 2019 Apr; 42():281-295. PubMed ID: 30878596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of CD47 on donor hepatocytes promotes innate immune cell activation and graft loss: a potential barrier to hepatocyte xenotransplantation.
    Navarro-Alvarez N; Yang YG
    Cell Transplant; 2014 Mar; 23(3):345-54. PubMed ID: 23394628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor CD47 controls T cell alloresponses and is required for tolerance induction following hepatocyte allotransplantation.
    Zhang M; Wang H; Tan S; Navarro-Alvarez N; Zheng Y; Yang YG
    Sci Rep; 2016 May; 6():26839. PubMed ID: 27230788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Proliferating Human Hepatocytes: In Vitro Hepatocyte Model for Drug Metabolism, Excretion, and Toxicity.
    Qiao S; Feng S; Wu Z; He T; Ma C; Peng Z; Tian E; Pan G
    Drug Metab Dispos; 2021 Apr; 49(4):305-313. PubMed ID: 33526515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical efficacy and safety of encapsulated proliferating human hepatocyte organoids in treating liver failure.
    Yuan X; Wu J; Sun Z; Cen J; Shu Y; Wang C; Li H; Lin D; Zhang K; Wu B; Dhawan A; Zhang L; Hui L
    Cell Stem Cell; 2024 Apr; 31(4):484-498.e5. PubMed ID: 38458193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 inhibition promotes hepatic regeneration in small-for-size liver following extended hepatectomy.
    Yan X; Shi JH; Xue JF; Guo WZ; Li B; Zhang SJ
    Cytokine; 2022 Nov; 159():156017. PubMed ID: 36054963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells.
    Lian S; Xie R; Ye Y; Lu Y; Cheng Y; Xie X; Li S; Jia L
    Sci Rep; 2019 Mar; 9(1):4532. PubMed ID: 30872703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 11. Single cell Raman spectroscopy to identify different stages of proliferating human hepatocytes for cell therapy.
    Ma C; Zhang L; He T; Cao H; Ren X; Ma C; Yang J; Huang R; Pan G
    Stem Cell Res Ther; 2021 Oct; 12(1):555. PubMed ID: 34717753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host conditioning and rejection monitoring in hepatocyte transplantation in humans.
    Soltys KA; Setoyama K; Tafaleng EN; Soto Gutiérrez A; Fong J; Fukumitsu K; Nishikawa T; Nagaya M; Sada R; Haberman K; Gramignoli R; Dorko K; Tahan V; Dreyzin A; Baskin K; Crowley JJ; Quader MA; Deutsch M; Ashokkumar C; Shneider BL; Squires RH; Ranganathan S; Reyes-Mugica M; Dobrowolski SF; Mazariegos G; Elango R; Stolz DB; Strom SC; Vockley G; Roy-Chowdhury J; Cascalho M; Guha C; Sindhi R; Platt JL; Fox IJ
    J Hepatol; 2017 May; 66(5):987-1000. PubMed ID: 28027971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ectopic expression of murine CD47 minimizes macrophage rejection of human hepatocyte xenografts in immunodeficient mice.
    Waern JM; Yuan Q; Rüdrich U; Becker PD; Schulze K; Strick-Marchand H; Huntington ND; Zacher BJ; Wursthorn K; DiSanto JP; Guzman CA; Manns MP; Ott M; Bock M
    Hepatology; 2012 Oct; 56(4):1479-88. PubMed ID: 22535707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma.
    Nan Y; Zhang X; Wang S; Xu C; Wang Y; Han L; Luan J; Hu X; Chen W; Cao Z; Zhu Z; Zeng X; Fan J; Ye L; Shi X; Ju D
    Immunotherapy; 2023 Feb; 15(3):175-187. PubMed ID: 36727256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Human CD200 Overexpression in Pig-to-Human Xenogeneic Immune Response Compared With Human CD47 Overexpression.
    Yan JJ; Koo TY; Lee HS; Lee WB; Kang B; Lee JG; Jang JY; Fang T; Ryu JH; Ahn C; Kim SJ; Yang J
    Transplantation; 2018 Mar; 102(3):406-416. PubMed ID: 28968355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.
    Yang Z; Xu J; Li R; Gao Y; He J
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3055-3065. PubMed ID: 31522278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
    Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J
    Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
    Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
    Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.